Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Forxiga in Patients With Type 2 Diabetes in Korea

Trial Profile

Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Forxiga in Patients With Type 2 Diabetes in Korea

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 08 Dec 2017 Results of a post-hoc analysis assessing efficacy and safety of dapagliflozin in real clinical settings (n=2008) presented at the 2017 Congress of the International Diabetes Federation
    • 10 Jun 2017 Biomarkers information updated
    • 02 Dec 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top